Dai­ichi Sankyo inks $183M dis­cov­ery deal with GPCR biotech for CNS tar­get

Bel­gian biotech Con­fo Ther­a­peu­tics has land­ed $183 mil­lion, plus po­ten­tial roy­al­ties, in a drug-dis­cov­ery deal with Dai­ichi Sankyo.

Ear­ly Thurs­day, Con­fo Ther­a­peu­tics put out word of the deal that will be fo­cused on small mol­e­cule an­tag­o­nists to go af­ter an undis­closed tar­get that the com­pa­ny says is as­so­ci­at­ed with CNS dis­eases.

Con­fo CEO Cedric Ververken told End­points News that Dai­ichi orig­i­nal­ly reached out to learn about the biotech’s tech­nol­o­gy. He added that Con­fo, found­ed in 2015, will use its plat­form to drug a GPCR tar­get that Dai­ichi has strug­gled with in­ter­nal­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER